drugset / Trial / NCT05266768
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002#
NaSingle-groupOpen-labelTreatment
Summary
An open label, single-arm clinical study evaluating the safety and efficacy of IBI346 infusion in relapsed/refractory multiple myeloma
Timeline
- Start
- 2022-04-28
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI346 Antibody | Protein / enzyme biologic | — | — |
| Subject | IBI346 CAR-T cell | Cell therapy | — | — |